Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, announces today the launch of a private placement of new ordinary shares to institutional investors. Cardio3 BioSciences intends to raise up to a maximum of 713,380 new shares (10% of the current share capital).
The new shares will be offered through a book-building procedure with institutional investors in Belgium and abroad. The Board of Directors has decided to waive the preferential subscription rights of the existing shareholders in the framework of this transaction with respect to the issuance of the new shares. The capital increase will take place within the limits of the authorised share capital as set out in the Company’s articles of association and in accordance with Article 604 of the Belgian Company Code.
The Company intends to use the proceeds from the proposed private placement to advance its product development efforts and for general working capital purposes. It may in the future consider additional financing transactions to fund its operations, which may include strategic transactions or additional private placement transactions or public offerings of securities.
The placement will start today, Thursday, 26 of February 2015, immediately following this announcement.
UBS Investment Bank will be acting as Global Coordinator and Bookrunner for the offering. Bryan, Garnier & Co and Petercam will act as Placement Agents.
The precise number of new shares to be issued and the subscription price per new share will be agreed by the Company and the Global Coordinator and the Placement Agents at the close of the bookbuilding process and the results of the placement will be announced as soon as practicable thereafter.
*** END ***
For more information, please contact:
Cardio3 BioSciences
Christian Homsy, CEO
Julie Grade, Corporate Communications Manager
www.c3bs.com
Tel: +32 10 39 41 00
jgrade@c3bs.com
For Europe: Consilium Strategic Communications
Amber Bielecka, Chris Welsh, Laura Thornton
Tel : +44 20 3709 5700
cardio3@consilium-comms.com
For the U.S: The Ruth Group
Lee Roth (Investors), Kirsten Thomas (Media)
Tel: +1 646 536 7012 / 7014
lroth@theruthgroup.com kthomas@theruthgroup.com
To subscribe to Cardio3 BioSciences’ newsletter, visit www.c3bs.com.
Follow us on Twitter @Cardio3Bio.
About Cardio3 BioSciences
Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA), and Dartmouth College (NH, USA). The Company’s lead product candidate in cardiology is C-Cure®, an autologous stem cell therapeutic using adult guided stem cells for the condition of congestive heart failure. The Company’s lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including hematologic cancers and solid tumors. Cardio3 BioSciences is also developing a portfolio of medical devices for enhancing the delivery of bio therapeutic agents into the myocardium
(C-Cathez®) and for cardiac surgery involving mitral valve defects.
Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.
To learn more about Cardio3 BioSciences, please visit www.c3bs.com
Important notices regarding the placement
The distribution of this press release in certain jurisdictions may be restricted by law. No action has been taken by the Company, UBS Investment Bank, the Placement Agents or any of their respective affiliates that would permit a public offer of the new shares in any jurisdiction where action for that purpose is required. This press release is for information purposes only and does not constitute an offer to purchase or the solicitation of an offer to buy any new shares in any jurisdiction in which such an offer or solicitation is unlawful. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.
Help employers find you! Check out all the jobs and post your resume.
